【摘要】 目的观察PCI术前口服血脂康对冠心病稳定型心绞痛患者介入治疗后心肌损伤标志物的影响。方法纳入冠心病稳定型心绞痛拟PCI治疗的患者74例,按照就诊顺序分为血脂康组(n=35例)和对照组(n=39例),血脂康组患者在术前在常规治疗的基础上口服血脂康1200mg/d共1周,对照组除未服血脂康外其他治疗均与血脂康组相同,两组患者分别于术前、术后10h、24h采集空腹静脉血3ml,对心肌损伤标志物:肌酸激酶同工酶MB(CK-MB),人心肌肌钙蛋白T(cardiac troponin T,CTnT),肌红蛋白(My-oglobin Myo)进行定量分析,并进行统计学处理。结果两组患者性别、年龄等临床资料相似无统计学差异,具有可比性,血脂康组CK-MB升高的患者所占比例显著低于对照组(11%对31%,P=0.044);两组cTnI升高的患者所占比例也差异显著(20%对46%,P=0.018);Myo虽然未表现出显著差异,但血脂康组与对照组相比也有降低趋势(23%对39%,P=0.127)。结论冠心病患者PCI术前预服血脂康可显著减少手术过程造成的心肌损伤。更多还原

【Abstract】 Objective To investigate the effects of Xuezhikang on blood levels of myocardial damage makers after percutaneous coronary intervention.Methods Seventy-four patients with chronic stable angina were enrolled in the study.Patients scheduled for elective coronary intervention were assigned to Xuezhikang(1200mg/d,n=35) or placebo(n=39) 7 days before the procedure according to in-hospital sequence.Creatine kinase-MB,troponin I,and myoglobin levels were measured at baseline and at 10 and 24 hours after the procedure.Results Detection of markers of myocardial injury above the upper normal limit was significantly lower in the Xuezhikang group versus the placebo group: for creatine kinase-MB: 11% versus 31%(P=0.044),20% versus 46% for troponin I(P=0.018),and 23% versus 39% for myoglobin(P=0.127).Conclusions Pretreatment with Xuezhikang 1200 mg/d for 7 days significantly reduce procedual myocardial injury in elective coronary intervention.更多还原